The Advanced Medical Technology Association (AdvaMed) is expressing disappointment with tariffs announced by the Trump administration, saying they will negatively impact American medical technology and innovation.
AdvaMed President and CEO Scott Whitaker issued a statement saying that broad-based tariffs of this nature would “act much as an excise tax.” He also called for the medtech industry to be exempted from these tariffs, citing how industries “with a meaningful humanitarian mission” have been exempted from broad tariffs.
Still, AdvaMed said it looks forward to continuing its conversations with the White House to help the administration understand the important role the medtech industry plays in the healthcare ecosystem, the value it provides to patients, and the importance of the industry to continued U.S. economic growth.
Leave a Reply